Breast cancer

Study finds no link between IVF and breast cancer risk

Researchers have found no increased risk of breast cancer among women who have undergone IVF, even after more than 20 years of follow up. …

Calcium channel blockers not linked to breast cancer risk

Analysis of data on 50,757 women conflicts with previous research that suggested calcium channel blockers increase breast cancer risk…

Bone drug could help prevent breast cancer in BRCA1 carriers

Blocking RANK ligand with denosumab reduced proliferation of breast cells from women at high genetic risk of breast cancer.…

Lowering cholesterol could help combat treatment resistant breast cancer

Blocking key enzymes in the cholesterol biosynthesis pathway reduced proliferation of cancer cells by 30–50%.…

Ten years of hormone therapy cuts breast cancer recurrence

Post-menopausal women with hormone receptor-positive early-stage breast cancer who take hormone therapy for ten years reduce the risk of their cancer recurring by 34% compared with those who take it for five years, according to the results of a clinical trial.…

Q&A: V Craig Jordan — the father of tamoxifen

V Craig Jordan, Dallas/Fort Worth living legend chair of cancer research, professor of both breast medical oncology and molecular and cellular oncology at the University of Texas MD Anderson Cancer Center in Houston, is best known as “the father of tamoxifen”.…

Improving long-term adjuvant anti-oestrogenic therapy for breast cancer

Long-term (five years) adjuvant tamoxifen treatment for oestrogen receptor-positive, or ER-positive, breast cancer post-surgery is recognised as a major advance in healthcare. Clinical trials comparing standard and extended tamoxifen therapy found a major decrease in mortality occurred in the ten ye…

Modified oestrogen could offer benefits of HRT without cancer risks

Women who take modified oestrogen could have the benefits of hormone replacement therapy without the potential for an increased risk of breast and uterine cancer, according to the results of a study.…

Study shows how stress increases breast cancer metastasis

Researchers suggest aggressive breast cancer could be slowed by targeting a specific signalling loop.…

Palbociclib drug combination slows advanced breast cancer

Combining the first-in-class targeted drug palbociclib with the hormone drug fulvestrant delays the progression of advanced breast cancer by an average of nine months — twice as long as when fulvestrant was given alone — a study shows.…